House Simple Resolution 1125
116th Congress(2019-2020)
Expressing support for prioritizing racial and ethnic diversity in clinical trials for therapies, diagnostics, and vaccines for COVID-19.
Introduced
Introduced in House on Sep 18, 2020
Origin Chamber
House
Type
Simple Resolution
Simple Resolution
A form of legislative measure introduced and potentially acted upon by only one congressional chamber and used for the regulation of business only within the chamber of origin. Depending on the chamber of origin, they begin with a designation of either H.Res. or S.Res. Joint resolutions and concurrent resolutions are other types of resolutions.
Bill Number
1125
Congress
116
Policy Area
Health
Health
Primary focus of measure is science or practice of the diagnosis, treatment, and prevention of disease; health services administration and funding, including such programs as Medicare and Medicaid; health personnel and medical education; drug use and safety; health care coverage and insurance; health facilities. Measures concerning controlled substances and drug trafficking may fall under Crime and Law Enforcement policy area.
Eliot Engel
grade
New York
Alabama
California
California
California
California
California
Connecticut
District of Columbia
Maryland
Massachusetts
New Jersey
New Jersey
New York
New York
New York
North Carolina
Tennessee
Texas
Texas
Virginia
No House votes have been held for this bill.
Summary
This resolution expresses the sense of the House of Representatives that federal agencies should take appropriate actions to (1) ensure meaningful engagement of communities of color in the conduct of COVID-19 (i.e., coronavirus disease 2019) research and participation in clinical trials, and (2) improve equitable access to safe and effective vaccines.
September 18, 2020
09/18/2020
Referred to the House Committee on Energy and Commerce.
09/18/2020
Introduced in House
Public Record
Record Updated
Jan 11, 2023 1:44:50 PM